

✓ -- THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40L)
MONOCLONAL ANTIBODY 5C8 IN THE TREATMENT OF
VASCULITIS --

IN THE ABSTRACT*

Please replace the Abstract with the following:

C1
-- Activation of cells bearing CD40 on their surface by
CD40 ligand is inhibited by contacting the cells with an agent
capable of inhibiting interaction between CD40 ligand and the
cells, in an amount effective to inhibit activation of the cells.
Activation of cells bearing CD40 on their surface by CD40 ligand
in a subject is inhibited by administering to the subject an
agent capable of inhibiting the interaction between CD40 ligand
and the cells, in an amount effective to inhibit activation of
the cells. Conditions dependent on CD40 ligand-induced
activation of CD40-bearing cells are treated, in particular
vasculitis. --

IN THE CLAIMS*

✓ Please cancel claims 1 and 102 to 144, without
prejudice.

Please add claims 145 to 166 as follows:

C2
145. (added) A method for treating vasculitis in a human,
other than a transplant recipient, comprising the step of
administering to said human an antibody, Fab, F(ab)'2 or a single
chain antibody, which binds specifically to an antigen
specifically bound by monoclonal antibody 5c8, produced by the
hybridoma having ATCC Accession No. HB 10916, wherein said

*The amendments to the Title and Abstract, are indicated
in the Appendix hereto (Exhibit A) for the Examiner's
convenience. The added claims are also set forth in the
Appendix.